Craig C. Hopkinson
CIK 1730048 · EVP R&D, Chief Medical Officer · last filed 2026-09-01
Craig C. Hopkinson is an EVP R&D, Chief Medical Officer who has filed 79 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for ALKS, was dated Sep 1, 2026. Across all open-market trades the lifetime net is −$24.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.23M
2
79
-$24.75M
Filer Profile
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | EVP R&D, Chief Medical Officer | 74,389 | $43.39 | $3.23M | -$24.75M | 55 | 2026-09-01 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | Director | 10,495 | $44.15 | $463.4K | $0 | 2 | 2023-03-02 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-01 | ALKS | Notice (144) | −9,000 | -$422.9K | EDGAR |
| 2026-09-01 | ALKS | Mixed | −4,000 | -$299.9K | EDGAR |
| 2026-08-03 | ALKS | Notice (144) | −9,000 | -$437.2K | EDGAR |
| 2026-08-03 | ALKS | Mixed | −4,000 | -$314.8K | EDGAR |
| 2026-07-01 | ALKS | Notice (144) | −9,000 | -$463.6K | EDGAR |
| 2026-07-01 | ALKS | Mixed | −4,000 | -$366.9K | EDGAR |
| 2026-06-01 | ALKS | Notice (144) | −9,000 | -$375.0K | EDGAR |
| 2026-06-01 | ALKS | Mixed | −4,000 | -$278.3K | EDGAR |
| 2026-05-01 | ALKS | Notice (144) | −9,000 | -$300.6K | EDGAR |
| 2026-05-01 | ALKS | Mixed | −4,000 | -$203.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.